Acute Intermittent Porphyria Market Report 2026

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.66 billion in 2025 to $4.97 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to limited availability of diagnostic facilities for aip, low awareness about acute intermittent porphyria, reliance on traditional treatment methods, increasing hospital and clinic infrastructure, growing demand for genetic testing.

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of novel therapies and hematin formulations, expansion of dna and enzyme testing services, increasing integration of telemedicine for rare diseases, rising awareness and educational programs for healthcare providers, adoption of advanced monitoring and digital health tools. Major trends in the forecast period include increased adoption of genetic and enzyme-based diagnostic tests, rising awareness about early diagnosis and management of aip, growth in prophylactic hematin infusions and targeted therapies, expansion of specialized treatment centers and research programs, integration of telemedicine and remote patient monitoring for aip patients.

The increasing prevalence of metabolic disorders is expected to drive the growth of the acute intermittent porphyria market in the coming years. Metabolic disorders encompass a range of conditions caused by abnormal chemical reactions in the body that interfere with normal metabolic processes. The growing occurrence of metabolic disorders is attributed to genetic predisposition, lifestyle-related factors, environmental influences, as well as improved awareness and diagnostic capabilities. This rise in metabolic disorders is prompting the pharmaceutical industry to invest more heavily in therapies for rare and genetic diseases, including acute intermittent porphyria. For example, in December 2023, according to the Cleveland Clinic, a US-based nonprofit academic medical center, inherited metabolic disorders collectively affect approximately 1 in 1,000 to 2,500 births globally. Therefore, the increasing prevalence of metabolic disorders is contributing to the growth of the acute intermittent porphyria market.

Leading companies operating in the acute intermittent porphyria market are concentrating on the development of innovative products, such as acute intermittent porphyria management tablets, to better meet patient needs with enhanced treatment options. Acute intermittent porphyria management tablets are oral medications designed to manage or prevent symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the approval of its Chlorpromazine Hydrochloride Tablets USP by the US Food & Drug Administration (USFDA) in strengths of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, available in these dosages, are used to manage symptoms of psychotic disorders and treat schizophrenia. They are also utilized to control nausea and vomiting, reduce restlessness and anxiety prior to surgery, and act as an adjunct therapy in the treatment of tetanus. Additionally, these tablets are employed in the management of acute intermittent porphyria, control manic episodes in manic-depressive illness, and provide relief from persistent hiccups.

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, entered into a partnership with Recordati Rare Diseases. Through this collaboration, the American Porphyria Foundation aims to increase awareness of porphyria and improve public understanding and support for acute intermittent porphyria. Recordati Rare Diseases is an Italy-based pharmaceutical company focused on the treatment of acute intermittent porphyria (AIP).

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

North America was the largest region in the acute intermittent porphyria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute intermittent porphyria market by increasing the cost of imported diagnostic kits, hematin formulations, and laboratory equipment, which has affected hospitals, specialized clinics, and research centers in regions like North America and Europe. The resulting increase in treatment and testing costs has slowed patient access and expanded operational expenses. On the positive side, tariffs have encouraged domestic production of hematin and diagnostic reagents, local research investments, and innovation in cost-effective therapies and monitoring solutions.

The acute intermittent porphyria market research report is one of a series of new reports that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute intermittent porphyria (AIP) is an uncommon inherited disorder that disrupts the production of heme, an essential component of hemoglobin in the blood. The condition is marked by periodic episodes of intense abdominal pain, gastrointestinal issues, and neurological manifestations such as muscle weakness, seizures, and mental disturbances, including anxiety, confusion, or hallucinations.

The primary diagnostic methods for acute intermittent porphyria include urine tests, blood tests, serum tests, DNA tests, and others. Urine testing involves examining a urine sample to identify increased levels of porphyrins or their precursors, which indicate the presence of acute intermittent porphyria (AIP). Available treatment options include prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and other therapies, and these are utilized in hospitals and clinics, ambulatory surgical centers, and research institutions.

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.